Cargando…

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening

MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iehara, T, Hosoi, H, Akazawa, K, Matsumoto, Y, Yamamoto, K, Suita, S, Tajiri, T, Kusafuka, T, Hiyama, E, Kaneko, M, Sasaki, F, Sugimoto, T, Sawada, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361271/ https://www.ncbi.nlm.nih.gov/pubmed/16670717 http://dx.doi.org/10.1038/sj.bjc.6603149

Ejemplares similares

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
por: Beiske, K, et al.
Publicado: (2009)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Experience with International Neuroblastoma Staging System and Pathology Classification
por: Ikeda, H, et al.
Publicado: (2002)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
por: Takahashi, Y, et al.
Publicado: (2014)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma
por: Honda, S, et al.
Publicado: (2008)

Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma
por: Xia, Yuren, et al.
Publicado: (2021)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
por: Ambros, P F, et al.
Publicado: (2009)

Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
por: Truong, M, et al.
Publicado: (2012)

Interleukin-6 gene amplification and shortened survival in glioblastoma patients
por: Tchirkov, A, et al.
Publicado: (2007)

Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase
por: Hiyoshi, H, et al.
Publicado: (2012)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells
por: Stockhausen, M-T, et al.
Publicado: (2005)

Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
por: Takeshita, H, et al.
Publicado: (2010)

RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
por: Misawa, A, et al.
Publicado: (2009)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon’s perspective
por: Chui, Chanhon
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition
por: Li, W, et al.
Publicado: (2009)

Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma
por: Kondo, S, et al.
Publicado: (2013)

MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer
por: Suzuki, S, et al.
Publicado: (2008)

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort
por: Tadeo, Irene, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
por: Betof, A S, et al.
Publicado: (2012)

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
por: Cihoric, N, et al.
Publicado: (2014)

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma
por: Panachan, Jirawan, et al.
Publicado: (2022)

Molecular detection of lymph node metastasis in breast cancer patients treated with preoperative systemic chemotherapy: a prospective multicentre trial using the one-step nucleic acid amplification assay
por: Osako, T, et al.
Publicado: (2013)

Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma
por: Kinoshita, A, et al.
Publicado: (2012)

Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma
por: Gattolliat, C-H, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_btag1m9904jtiq5mjbiko5rnvr